AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL).
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell lymphoma, a life-threatening form of blood cancer. These data reinforce the important progress of our clinical development programme as well as our commitment to advancing the treatment of patients with blood cancers.”
Michael L. Wang, MD, Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, and Principal Investigator of the ACE-LY-004 MCL clinical trial, said: “Most people living with mantle cell lymphoma will unfortunately relapse, and new treatment options are greatly needed. As shown by the consistent overall response rates observed in this trial across several pre-specified subgroups, acalabrutinib is a welcome new treatment option for certain patients with this aggressive blood cancer.”
Summary of key investigator-assessed efficacy results from ACE-LY-004 (15.2 months median follow-up):
|Efficacy measure||Patients (percent response)|
Overall response rate
81% (95% CI: 73,87)
40% (95% CI: 31,49)
41% (95% CI: 32,50)
|Stable disease||9% (95% CI: 5,15)|
|Progressive disease||8% (95% CI: 4,14)|
|Not evaluable||2% (95% CI: 1,7)|
Per the 2014 Lugano classification response criteria for non-Hodgkin lymphoma; high concordance was observed between investigator-assessed and independent review committee-assessed overall response and complete response rates, respectively.
The overall response rate was consistent across multiple subgroups including age, tumour burden and number or type of prior treatments. The secondary endpoint of median duration of response had not yet been reached at 15.2 months median follow-up. The median time-to-response, an exploratory endpoint, was 1.9 months. After 12 months of treatment, 72% (95% CI: 62,80) of patients were still responding to acalabrutinib treatment. The secondary endpoints of progression-free survival and overall survival had not yet been reached; at 12 months, the progression-free survival and overall survival rates were 67% (95% CI: 58,75) and 87% (95% CI: 79,92), respectively.
In this trial, the most common non-haematological adverse reactions (reported in ≥20% of patients at a median follow-up time of 15.2 months) were headache (38%), diarrhoea (30%), fatigue (26%) and myalgia (21%), per investigator assessment. Grade 3 or 4 adverse reactions (≥5%) included anaemia (12%), neutropenia (11%), and pneumonia (6%).
Calquence was granted accelerated approval by the US FDA in October 2017 for the treatment of adult patients with MCL who have received at least one prior therapy. This indication is approved based on overall response rate, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
– ENDS –
NOTES TO EDITORS
About Calquence (acalabrutinib)
Acalabrutinib (previously known as ACP-196) is a selective inhibitor of BTK. Acalabrutinib binds covalently to BTK, thereby inhibiting its activity, and has demonstrated this with minimal interactions with other immune cells in pre-clinical studies.2,3,4 In B cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis and adhesion.2
Calquence was granted accelerated approval by the US Food and Drug Administration (FDA) in October 2017 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Acalabrutinib is not approved for use outside of its labelled indication in the US and is not approved in any other country at this time.
Acalabrutinib is also in development for the treatment of multiple B-cell malignancies and other blood cancers including 1st-line MCL, chronic lymphocytic leukaemia (CLL), Waldenström macroglobulinaemia (WM), follicular lymphoma, diffuse large B-cell lymphoma, and multiple myeloma. It is also being developed as a monotherapy and in combination trials for solid tumours. More than 35 clinical trials across 40 countries with more than 2,500 patients are underway or have been completed.5
Acalabrutinib was granted Orphan Drug Designation by the European Commission in March 2016 and the US FDA in 2015 for the treatment of patients with CLL, MCL and WM, and Breakthrough Therapy Designation in August 2017 by the US FDA for the treatment of patients with MCL who have received at least one prior therapy.
About Mantle Cell Lymphoma (MCL)
MCL is an aggressive B-cell non-Hodgkin lymphoma (NHL) with poor prognosis.6,7,8,9 MCL accounts for approximately 3% to 6% of new NHL cases in Western countries each year; in the US, approximately 3,300 new cases of MCL are diagnosed each year.6,10 The median age at diagnosis is 68 years, with a 3:1 male predominance.7 While MCL patients initially respond to treatment, there is a high relapse rate.6
About the ACE-LY-004 Trial
ACE-LY-004 is a Phase II open-label, single-arm clinical trial in 124 adult patients with relapsed or refractory MCL. The trial showed that 81% (95% CI: 73,87) of patients treated with acalabrutinib achieved an overall response; 40% (95% CI: 31,49) achieved a complete response and 41% (95% CI: 32,50) achieved a partial response, per 2014 Lugano classification as assessed by investigator.1
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that have the potential to transform patients’ lives and the Company’s future. With at least six new medicines aimed to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s five Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
About Acerta Pharma
Acerta Pharma, a member of the AstraZeneca Group, is creating novel therapies intended for the treatment of cancer and autoimmune diseases. AstraZeneca acquired a majority stake interest in Acerta Pharma, which serves as AstraZeneca’s haematology research and development centre of excellence. For more information, please visit www.acerta-pharma.com.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
This press release is issued from AstraZeneca Corporate Headquarters in Cambridge, UK and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where AstraZeneca conducts business.
1 Data on File. REF-23706. AstraZeneca Pharmaceuticals
LP, Wilmington, DE.
Karen Birmingham: +44 781 852 4012
Mike Hayes: +1 301-398-0221
Hugues Joublin: +1 301-398-3041
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
SIFLEX Switches to Rimini Street Support for Its SAP Application23.4.2018 23:00 | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that SIFLEX, a leading global printed circuit board (PCB) manufacturer headquartered in South Korea, has switched its SAP ERP support to Rimini Street from the vendor. By making the switch, SIFLEX was able to reduce its maintenance fees by 50% and can now maximize its current, stable and robust ERP ECC 5.0 system for a minimum of 15 years from the time the company transitioned to Rimini Street support. SIFLEX was also able to free up internal IT personnel to focus on more pressing initiatives within the organization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423006227/en/ Leading Korean manufacturer of printed circuit boards, SIFLEX, Switches to Rimini Street Support for its SAP Application (Photo: Business Wire) Seeking
REPLY S.p.A.: Shareholders’ Meeting Approves the 2017 Financial Statements23.4.2018 15:10 | Pressemelding
Consolidated turnover of €884.4 million (+13.3%); Group net profits of €77.9 million (+ 15.3%). The proposal to distribute a dividend of €0.35 per share has been approved. The Board of Directors and the Board of Statutory Auditors have been appointed for the three-year period 2018-2020. Resolutions in relation to the purchase and/or sale of own shares. Reply S.p.A. Shareholders’ meeting [MTA, STAR: REY] today approved the Financial Statements for the financial year 2017, confirming the distribution of a gross dividend of €0.35 per share (up 21.7% compared to the previous year, taking into consideration the equity split occurred in October 2017, which converted each ordinary share, having a nominal value of €0.52 into 4 new ordinary shares, nominal value of €0.13). The dividend will be paid on 9 May 2018, with dividend detachment date set on 7 May 2018 and record date 8 May 2018. Financial Statements of the 2017 financial year The Reply Group closed the 2017 financial year with a consol
ABB and the Economist Launch Automation Readiness Index, Global Ranking for Robotics and Artificial Intelligence23.4.2018 14:35 | Pressemelding
South Korea, Germany and Singapore are the world’s top-ranked nations in their preparations for smoothly integrating intelligent automation into their economies, according to an index and report released today by ABB and The Economist Intelligence Unit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005873/en/ The report "The Automation Readiness Index (ARI): Who Is Ready for the Coming Wave of Innovation?" finds that even the best-prepared countries must develop even more effective education policies and training programs, as well as place a new emphasis on continual learning over the course of a career. Those policies and programs, the report recommends, must ensure that the rapid adoption of automation technologies and artificial intelligence (AI) will not leave people unprepared for the new, more human-oriented jobs that will be needed as robots and algorithms take on more of the routine tasks that can be and will
Finablr Launched To Accelerate Customer-Focused Technology Innovations23.4.2018 12:55 | Pressemelding
Noted UAE-based businessman and philanthropist, Dr. Bavaguthu Raghuram Shetty announced the creation of “Finablr”, a new holding company which, subject to regulatory approvals, will consolidate his global portfolio of financial services brands under one single umbrella. Incorporated in the UK, Finablr will provide strategic direction and oversight for the category-leading brands across its network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005741/en/ Finablr Leadership Team (L-R): Binay Shetty (Executive Director, Finablr), Dr. B.R. Shetty (Founder and Chairman, Finablr) and Promoth Manghat (Executive Director, Finablr) (Photo: AETOSWire) Finablr also seeks to drive financial enablement and empowerment by accelerating customer-focused technology innovation through R&D efforts, industry ecosystem engagements, investments and potential acquisitions. As a diversified network, Finablr will combine the cumulative indus
Abu Dhabi Fund for Development Finances US$192 Million Sheikh Khalifa bin Zayed City in Afghanistan23.4.2018 12:37 | Pressemelding
His Excellency Mohammad Ashraf Ghani, President of Afghanistan, inaugurated the Abu Dhabi Fund for Development (ADFD) financed Sheikh Khalifa bin Zayed City Housing Complex in Afghanistan. Located in the Qasaba district of Afghanistan’s capital Kabul, ADFD contributed an estimated US$192 million to the social housing development project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005711/en/ His Excellency Mohammed Saif Al Suwaidi, Director General of ADFD, during the official inauguration ceremony of the 3,330-residential unit Sheikh Khalifa bin Zayed City in Afghanistan (Photo: AETOSWire) Aimed at increasing the supply of affordable accommodation options in the country, the crucial project encompasses 3,330 residential units. Including extensive infrastructure works such as roads, water, and electricity networks and support services, the project seeks to elevate living standards for its residents through its power
Rockwell Automation Simplifies Analytics for Industrial Productivity23.4.2018 12:00 | Pressemelding
Industrial organizations must be able to quickly identify ways to tighten production schedules and maximize revenue. Gaining insight into operations and production capabilities to make informed decisions has often involved time-intensive IT projects and a highly specialized skillset. Today, Rockwell Automation expands the FactoryTalk® Analytics portfolio, a robust advanced analytics environment that empowers users with the ability to quickly and confidently make informed decisions. These latest advancements were developed to reduce the complexity of the operations environment for manufacturers and producers and their employees who are driving operations. FactoryTalk Analytics has been developed for scale, discovering and connecting data sources from the edge of the network up through the enterprise, and then intelligently fusing the information to resolve issues close to the source. At the edge or the device, this can result in near-immediate resolution of production issues. Empowered